Pate4 Inhibitors
Pate4 inhibitors are a class of chemical compounds characterized by their ability to selectively interact with the phosphatidylethanolamine-binding protein 4 (PATE4). PATE4 is a member of the PATE protein family, which plays a role in various biological processes due to its interaction with phospholipids, such as phosphatidylethanolamine (PE). The inhibitors targeting PATE4 typically possess a specific molecular architecture that allows them to bind with high affinity to the active or allosteric sites of this protein. By doing so, they can modulate the function of PATE4, which may have a cascade of effects on the molecular pathways in which PATE4 is involved. The design of Pate4 inhibitors is often guided by detailed structural knowledge of PATE4, acquired through techniques such as X-ray crystallography or NMR spectroscopy. This information is critical in understanding the binding pockets and conformational dynamics of the protein, which are essential for the development of highly selective inhibitors.
The development of Pate4 inhibitors involves a rigorous process of chemical synthesis and characterization. These molecules can vary significantly in their size, complexity, and chemical nature, ranging from small organic molecules to larger biopolymeric structures. The chemical synthesis of such inhibitors often requires multiple steps, including the formation of various chemical bonds and the introduction of functional groups that are key for interaction with PATE4. Once synthesized, Pate4 inhibitors are typically subjected to a series of analytical techniques to confirm their purity, structure, and stability. Such techniques may include mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and high-performance liquid chromatography (HPLC). The physical and chemical properties of these inhibitors, such as solubility, lipophilicity, and chemical reactivity, are also characterized thoroughly to gain a comprehensive understanding of how they interact with PATE4 at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that blocks the epidermal growth factor receptor signaling pathway. Pate4, if it were found to be a downstream effector of EGFR, would be indirectly inhibited as the blockade of EGFR signaling would prevent its activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR signaling pathway which is critical for regulating cell growth and proliferation. If Pate4 activity is linked to mTOR pathway outputs, rapamycin would indirectly inhibit Pate4 by reducing pathway activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT, downstream of PI3K. If Pate4 is activated by the PI3K/AKT pathway, its activity would be decreased due to LY294002's inhibitory action on this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter gene expression patterns. If the expression of Pate4 is regulated by acetylation status, this compound could indirectly decrease Pate4 expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that interferes with the MAPK/ERK signaling pathway. Should the activity of Pate4 be regulated by this pathway, inhibition of MEK by U0126 could lead to reduced activity of Pate4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that impedes the p38 MAPK stress-activated pathway. If Pate4 is a stress-responsive protein regulated by p38 MAPK, SB203580 would indirectly inhibit Pate4 by blocking this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which also acts on the MAPK/ERK pathway. If Pate4 relies on this pathway for its activation, PD98059 would lead to an indirect inhibition of Pate4 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that, by inhibiting the JNK signaling pathway, could decrease the activity of Pate4 if it is regulated by or acts as part of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002 but is irreversible. It would similarly inhibit Pate4 by preventing PI3K-dependent activation processes if Pate4 is involved in this signaling cascade. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that disrupts actin cytoskeleton organization and cell motility. If Pate4 activity is associated with cellular structures affected by ROCK, Y-27632 would lead to its functional inhibition. | ||||||